ECMO blood thinner showdown: which drug wins?
NCT ID NCT05959252
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two blood thinners, bivalirudin and heparin, in 80 adults on ECMO (a heart-lung machine). The goal is to see which drug keeps blood thin enough to prevent clots and bleeding, and which is more cost-effective. Participants are randomly assigned to one of the two drugs.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTRACORPOREAL MEMBRANE OXYGENATION COMPLICATION are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Royal Prince Alfred Hospital
RECRUITINGSydney, New South Wales, 2050, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood test may forecast life-threatening clots or bleeds on ECMO
- Portable MRI could spot brain injury in children on life support
- ECMO Patients' hidden infection risk under the microscope
- ECMO breakthrough? major trial aims to cut deadly complications
- New study aims to uncover why ECMO patients bleed
- Could 'lung rest' on ECMO save more lives in severe ARDS?